Wyeth’s Xyntha Wins FDA Nod For Hemophilia A
This article was originally published in The Pink Sheet Daily
Executive Summary
Factor VIII is made by modifying genes from Chinese hamster ovary cells to reduce infection risk.
You may also be interested in...
Dyax Restructures Royalty Loan Agreement, Bringing In $15 Million
Extension of royalty-sharing with Cowen Healthcare Royalty Partners enables Dyax to fund itself while awaiting FDA’s decision on ecallantide – but at a steep price.
Dyax Restructures Royalty Loan Agreement, Bringing In $15 Million
Extension of royalty-sharing with Cowen Healthcare Royalty Partners enables Dyax to fund itself while awaiting FDA’s decision on ecallantide – but at a steep price.
ZymoGenetics Will Ship Topical Hemostat Recothrom In Two Weeks
Company will price the recombinant, plasma-free thrombin at a 20 percent premium over competitor King's bovine-derived Thrombin JMI.